Abstract Number: 53 • 2018 ACR/ARHP Annual Meeting
Cyclin-Dependent Kinase 4/6 Inhibitor: A Promising Development Candidate Targeting Synovial Hypertrophy for Rheumatoid Arthritis Treatment
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the hypertrophy of synovial fibroblasts,…Abstract Number: 347 • 2018 ACR/ARHP Annual Meeting
Effectiveness of a Biopsychosocial Exercise Approach in Rheumatic Diseases
Background/Purpose: The trend towards biopsychosocial approaches is increasing today and studies on psychosocial effects of exercise are limited in the literature. There is a need…Abstract Number: 425 • 2018 ACR/ARHP Annual Meeting
Efficacy, Safety, and Tolerability of ONO-4474, an Orally Available Pan-Tropomyosin Receptor Kinase Inhibitor, in Japanese Patients with Moderate-to-Severe Osteoarthritis of the Knee: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Study
Background/Purpose: ONO-4474 is an orally available, peripheral-specific, pan-tropomyosin receptor kinase (pan-Trk) inhibitor currently under development for treatment of musculoskeletal pain in OA patients. This study…Abstract Number: 934 • 2018 ACR/ARHP Annual Meeting
HIV Protease Inhibitors Cure Lupus-Prone Mice and Prevent T Helper 17 Cell-Driven Inflammation By Inhibiting CD95-Non-Apoptotic Signaling Pathway
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by loss of tolerance to nuclear components; this results in production of autoantibodies, immune…Abstract Number: 1935 • 2018 ACR/ARHP Annual Meeting
Multiple Dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP5094, an Anti-Alpha9 Integrin Monoclonal Antibody, in Patients with Rheumatoid Arthritis on Methotrexate
Background/Purpose: Joint synovium is the main tissue involved in rheumatoid arthritis (RA) lesions. Alpha9 integrin is expressed by synovial tissue lining cells and has been…Abstract Number: 1794 • 2017 ACR/ARHP Annual Meeting
Overexpression of Interleuk-22 Induces Expression of the Negative Immune-Regulator SOCS3 and Potently Reduces Collagen-Induced Arthritis in Mice
Background/Purpose: High interleukin-22 (IL-22) levels are detected in serum and synovial fluid of rheumatoid arthritis (RA) patients and have been shown to positively correlate with…Abstract Number: 258 • 2015 ACR/ARHP Annual Meeting
Quality of Life Changes with Canakinumab Therapy in Adults with Colchicine Resistant FMF
Background/Purpose: Introduction:Familial Mediterranean Fever (FMF), the most common form of the hereditary autoinflammatory disorders, is characterized by recurrent attacks of fever along with serosal or…Abstract Number: 901 • 2015 ACR/ARHP Annual Meeting
Novel B Cell-Derived Peptide Regulation of Homeostatic T-Cell Trafficking Is Subverted in Rheumatoid Arthritis
Background/Purpose: In rheumatoid arthritis (RA), inappropriate recruitment of T-cells into the joint contributes to disease pathogenesis and joint destruction. We examined the ability of adiponectin…Abstract Number: 1661 • 2015 ACR/ARHP Annual Meeting
Translational Data and Phase 1 Study Results of a New Monoclonal Antibody Targeting Toll like Receptor 4 (TLR4) Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine
Background/Purpose: Innate immunity is implicated in RA pathogenesis and is likely mediated via TLR pathways, with anti-citrullinated protein antibodies (ACPA) serving as key triggers. NI-0101…Abstract Number: 2776 • 2015 ACR/ARHP Annual Meeting
Profiling Compounds in Human Primary Cell-Based Disease Models Guide Indication Selection
Background/Purpose: In vitro co-cultures of human primary cells, including immune cells, fibroblasts, smooth muscle, keratinocytes, epithelial or endothelial cells were developed to capture the complexity…Abstract Number: 3082 • 2015 ACR/ARHP Annual Meeting
Nanogel Based Delivery of an Inhibitor of Calcium/ Calmodulin- Dependent Protein Kinase 4 Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice
Background/Purpose: Treatment of autoimmune diseases is still based on the use of general immunosuppressive drugs which invariably cause severe side effects. This fact has compelled…Abstract Number: 3191 • 2015 ACR/ARHP Annual Meeting
Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages
Background/Purpose: Siglecs (Sialic acid-binding immunoglobulin-type lectins) are type1 transmembrane proteins and expressed on cell surface of various immunocytes. Siglec9 is a member of CD33 related…Abstract Number: 3219 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of 4 Weeks Administration of Arsenic Trioxide in Moderate Active Systemic Lupus Erythematosus. a Phase I/II Proof-of-Concept Sequential Dose Escalation Multicenter Study
Background/Purpose: Arsenic Trioxide (ATO) is approved for the treatment of acute promyelocytic leukemia, increasing oxidative stress with selective apoptosis of leukemia cells. In MLR/lpr model…Abstract Number: 1484 • 2014 ACR/ARHP Annual Meeting
Discovery of ARN-4079 – a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis
Background/Purpose: The Non-receptor tyrosine kinases, JAK3 and ITK are key regulators of cytokine pathways and are important clinically validated targets, which offer the potential for…Abstract Number: 1498 • 2014 ACR/ARHP Annual Meeting
ALX-0061, an Anti-IL-6R Nanobody® for use in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab
Background/Purpose Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor, which can either be soluble (sIL-6R) or membrane-bound…
ACR Meeting Abstracts